A prospective study compared KRAS mutation results obtained from plasma cfDNA testing with those obtained from tumor tissue biopsy and showed that plasma cfDNA analysis exhibited 98% specificity and 92% sensitivity, with a concordance rate of 96% [24]. Here, KRAS is linked to neoplasm.